论文部分内容阅读
背景:在美国,每年有100万以上例次因心力衰竭而住院,多与充血有关。托伐普坦是一种口服的非肽类拮抗剂,可选择性阻断血管加压素V2受体。研究显示托伐普坦有望用于治疗心力衰竭。目的:评估心力衰竭住
Background: In the United States, there are more than 1 million cases of hospitalizations due to heart failure each year, mostly related to congestion. Tolvaptan is an oral non-peptide antagonist that selectively blocks the vasopressin V2 receptor. Research shows that tolvaptan is expected to be used to treat heart failure. Purpose: To assess heart failure